CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,308,097 | +631.5% | 1,026,700 | +327.8% | 0.24% | +490.0% |
| Q1 2023 | $2,092,800 | +75.7% | 240,000 | +26.3% | 0.04% | +122.2% |
| Q4 2022 | $1,191,300 | +242.3% | 190,000 | +90.0% | 0.02% | +350.0% |
| Q3 2022 | $348,000 | -15.5% | 100,000 | -28.6% | 0.00% | -20.0% |
| Q2 2022 | $412,000 | +9.9% | 140,000 | +16.7% | 0.01% | +25.0% |
| Q1 2022 | $375,000 | -40.4% | 120,000 | -33.3% | 0.00% | -80.0% |
| Q2 2020 | $629,000 | +192.6% | 179,900 | +499.7% | 0.02% | +81.8% |
| Q2 2019 | $215,000 | – | 30,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |